We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CEPI, SK Biopharma to Develop ‘Variant-Proof’ COVID-19 Vaccine
CEPI, SK Biopharma to Develop ‘Variant-Proof’ COVID-19 Vaccine
CEPI, the Coalition for Epidemic Preparedness Innovations, has joined with Korean biopharma firm SK Biopharma (SK) to develop a “variant-proof” vaccine that would protect against a large coronavirus subgenus that includes the SARS-CoV-2 virus that causes COVID-19.